WIPO logo
Mobile | Deutsch | Español | Français | 日本語 | 한국어 | Português | Русский | 中文 | العربية |

Search International and National Patent Collections
World Intellectual Property Organization
Machine translation
Latest bibliographic data on file with the International Bureau    Submit observation

Pub. No.:    WO/2017/185949    International Application No.:    PCT/CN2017/079303
Publication Date: 02.11.2017 International Filing Date: 01.04.2017
C07K 16/28 (2006.01), C12N 15/13 (2006.01), C12N 15/85 (2006.01), C12N 5/10 (2006.01), A61K 39/395 (2006.01), A61P 35/00 (2006.01)
Applicants: ZHAO, Lei [CN/CN]; (CN)
Inventors: ZHAO, Lei; (CN).
ZHANG, Fan; (CN)
Agent: LECOME INTELLECTUAL PROPERTY AGENT LTD.; Fl.16, Tower B, INDO Mansion, No.48-Jia Zhichun Road, Haidian District Beijing 100098 (CN)
Priority Data:
201610257652.2 24.04.2016 CN
(ZH) 一种抗CD20靶向抗体
Abstract: front page image
(EN)A novel CD20 antibody and an application thereof in preparing anti-tumor drugs, and more specifically, a novel CD20 antibody having advantages of type I and II CD20 antibodies, a nucleic acid sequence and an amino acid sequence thereof, and an application thereof in preparing anti-tumor drugs. This antibody not only reserves the function of type I CD20 antibody of inducing strong CDC killing, but also has the advantage of type II CD20 antibody of inducing strong cell death, and thus has an anti-tumor activity better than those of the parental type I CD20 antibody Rituximab and type II CD20 antibody, thereby having great potential applications.
(FR)L'invention concerne un nouvel anticorps anti-CD20 et une application de celui-ci dans la préparation de médicaments anti-tumoraux, et plus spécifiquement, un nouvel anticorps anti-CD20 ayant les avantages d'anticorps anti-CD20 de type I et II, une séquence d'acide nucléique et une séquence d'acides aminés de celui-ci, ainsi qu'une application de celui-ci dans la préparation de médicaments anti-tumoraux. Cet anticorps non seulement conserve la fonction de l'anticorps anti-CD20 de type I d'induction d'une forte destruction des CDC, mais aussi possède l'avantage d'un anticorps anti-CD20 de type II d'induction d'une mort cellulaire forte, et présente donc une activité antitumorale meilleure que celles de l'anticorps anti-CD20 de type I parent Rituximab et de l'anticorps anti-CD20 de type II, permettant ainsi de vastes applications potentielles.
Designated States: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.
African Regional Intellectual Property Organization (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW)
Eurasian Patent Organization (AM, AZ, BY, KG, KZ, RU, TJ, TM)
European Patent Office (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR)
African Intellectual Property Organization (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).
Publication Language: Chinese (ZH)
Filing Language: Chinese (ZH)